one hundred patients with stage iii and iv epithelial ovarian cancer participated in a prospective randomized study to determine whether the addition of tamoxifen , an estrogen agonist-antagonist , to standard cytotoxic chemotherapy ( doxorubicin , cis-diamminedichloroplatinum ) would significantly improve survival .
C0039286
tamoxifen
C3536982
estrogen agonist-antagonist